

- Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T. (2004). Protein tyrosine phosphatases in the human genome. *Cell* 117: 699–711.
- Aubin JE, Liu F. (1996). The osteoblast lineage. In: Bilezikian JP, Raisz LG & Rodan GA (eds) *Principles of Bone Biology*. Academic Press, San Diego, p 51- 67.
- Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA. (1993). The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. *J Clin Invest* 92: 2577–2586.
- Bellido T., Borba VZC, Roberson PK, Manolagas SC.. (1997). Activation of the JAK/STAT signal transduction pathway by the IL-6 type cytokines promotes osteoblast differentiation. *Endocrinology* 138: 3666-3676.
- Bellido T, Plotkin LI. (2010). Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability, *Bone* doi:10.1016/j.bone.2010.08.008.
- Bianchi C, Sellke FW, Del Vecchio RL, Tonks NK, Neel BG. (1999). Receptor-Type Protein-Tyrosine Phosphatase μ Is Expressed in Specific Vascular Endothelial Beds *in Vivo*. *Experimental Cell Research* 248: 329–338.
- Bilwes AM, den Hertog J, Hunter T, Noel JP. (1996). Structural basis for inhibition of receptor proteintyrosine phosphatase- α by dimerization. *Nature* 382: 555–559.

- Blanchetot C, Tertoolen LG, Overvoorde J, den Hertog J. (2002). Intra- and intermolecular interactions between intracellular domains of receptor proteintyrosine phosphatases. *J. Biol. Chem.* 277: 47263–47269.
- Bonewald LF. (1999). Establishment and characterization of an osteocyte-like cell line, MLO- Y4. *J Bone Miner Metab* 17: 61-65.
- Bradford MM. (1976). A rapid and sensitive method for quantification of microgram quantities of proteins utilizing the principle of protein binding. *Anal Biochem* 72: 248-254.
- Brondello JM, Pouysségur J, McKenzie FR. (1999). Reduced MAP kinase phosphatase-1 degradation after p42/p44 MAPK-dependent phosphorylation. *Science*. 24;286(5449):2514-7.
- Buist, A. et al. (1999). Restoration of potent protein-tyrosine phosphatase activity into the membrane-distal domain of receptor protein-tyrosine phosphatase alpha. *Biochemistry* 38: 914–922.
- Burger EH, Klein-Nulend J. (1999). Mechanotransduction in bone-role of the lacuno-canalicular network. *FASEB J* 13 Suppl: S101- S112.
- Camps M, Nichols A, Arkinstall S. (2000). Dual specificity phosphatases: a gene family for control of MAP kinase function. *FASEB J*. 14: 6–16.
- Carr G, Moochhala SH, Eley L, Vandewalle A, Simmons NL, Sayer JA. (2009). The Pyrophosphate Transporter ANKH is Expressed in Kidney and Bone Cells and Colocalises to the Primary Cilium/Basal Body Complex. *Cell Physiol Biochem* 24:595-604.
- Charbonneau H, Tonks NK, Kumar S, Diltz CD, Harrylock M, Cool DE, Krebs EG, Fischer EH, Walsh KA. (1989). Human placenta protein-tyrosine-

phosphatase: Amino acid sequence and relationship to a family of receptor-like proteins. *Proc Natl Acad Sci USA* 86:5252–5256.

Civitelli R, Beyer EC, Warlow PM, Robertson AJ, Geist ST, Steinberg TH. (1993). Connexin43 mediates direct intercellular communication in human osteoblastic cell networks. *J Clin Invest* 91: 1888-1896.

Coleman RE. (2005). Bisphosphonates in breast cancer. *Annals of Oncology* 16: 687–695.

Cooper S. (2003). Reappraisal of serum starvation, the restriction point, G₀, and G₁ phase arrest points. *FASEB J* 17: 333-40.

Coxon FP, Thompson K, Roelofs AJ et al. (2008). Visualizing mineral binding and uptake of bisphosphonates by osteoclasts and non-resorbing cells. *Bone* 42: 848–860.

Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. (2002). Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. *Am J Med* 112: 281-89.

Del Vecchio RL, Tonks NK. (2005). The Conserved Immunoglobulin Domain Controls the Subcellular Localization of the Homophilic Adhesion Receptor Protein-tyrosine Phosphatase μ . *The Journal of Biological Chemistry*. 280: 1603–1612.

den Hertog J, Tracy S, Hunter T. (1994). Phosphorylation of receptor protein-tyrosine phosphatase α on Tyr789, a binding site for the SH3-SH2-SH3 adaptor protein GRB-2 in vivo. *The EMBO Journal*. 13: 3020-3032.

den Hertog J, Sap J, Pals CE, Schlessinger J, Kruijer W. (1995). Stimulation of Receptor Protein-Tyrosine Phosphatase α Activity and Phosphorylation by Phorbol Ester. *Cell Growth & Differentiation*. 6: 303-307.

den Hertog J, Oostman A, Böhmer FD. (2008). Protein tyrosine phosphatases: regulatory mechanisms. *FEBS Journal* 275: 831-847.

Doty SB (1981) Morphological evidence of gap junctions between bone cells. *Calcified Tissue Int* 33: 509- 512.

Dunford JE, Thompson K, Coxon FP et al. (2001). Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. *The Journal of Pharmacology and Experimental Therapeutics* 296: 235-242.

Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A. (1996). *J. Bone Miner. Res.* 11: 535-543.

Engelbrecht Y, Wet H, Horsch K, Langeveldt CR, Hough FS, Hulley PA. (2003). Glucocorticoids Induce Rapid Up-Regulation of Mitogen-Activated Protein Kinase Phosphatase-1 and Dephosphorylation of Extracellular Signal-Regulated Kinase and Impair Proliferation in Human and Mouse Osteoblast Cell Lines. *Endocrinology* 144(2):412-422.

Farooq A, Zhou MM. (2004). Structure and regulation of MAPK phosphatases. *Cellular Signal* 16: 769-779.

Felberg J, Johnson P. (1998). Characterization of recombinant CD45 cytoplasmic domain proteins. Evidence for intramolecular and intermolecular interactions. *J. Biol. Chem.* 273: 17839-17845.

- Felsenberg D, Boonen S. (2005). The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. *Clin Ther.* 27: 1-11.
- Finkel, T. Oxidant signals and oxidative stress. (2003). *Curr. Opin. Cell Biol.* 15: 247-254.
- Fleisch H. (1997). *Bisphosphonates In Bone Diseases. From The Laboratory To The Patient. Third Edition.* The Parthenon Publishing Group Inc. London.
- Fleisch H. (1998). Bisphosphonates: mechanisms of action. *Endocr Rev* 19: 80-100.
- Frith JC, Monkkonen J, Blackburn GM, Russell GG, Rogers MJ. (1997). Clodronate and Liposome-Encapsulated Clodronate Are Metabolized to a Toxic ATP Analog, Adenosine 59-(b,g Dichloromethylene) Triphosphate, by Mammalian Cells In Vitro. *J Bone Min Res* Volume 12, Number 9.
- Ge C, Xiao G, Jiang D, Franceschi RT. (2007). Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. *The Journal of Cell Biology.* 176: 709-718.
- Giepmans BN, Hengeveld T, Postma FR, Moolenaar WH. (2001). Interaction of c-Src with gap junction protein connexin-43: role in the regulation of cell-cell communication. *J Biol Chem* 276: 8544-49.
- Giepmans BN. (2004). Gap junctions and connexin-interacting proteins. *Cardiovascular Research.* 62: 233- 245.

- Giepmans BN; Feiken E; GebbinK MF, Moolenaar WH. (2003). Association of connexin43 with a receptor protein tyrosine phosphatase. *Cell Commun Adhes.* 10: 201-5.
- Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. (1998). Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. *Bone* 22: 455-61.
- Giuliani N, Pedrazzoni M, Passeri G, Girasole G. (1998). Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. *Scand J Rheumatol*; 27: 38-41.
- Goodenough DA, Goliger JA, Paul DL. (1996). Connexins, connexons, and intercellular communication. *Annu Rev Biochem* 65: 475-502.
- Hervé JC, Bourmeyster N, Sarrouilhe D. (2004). Diversity in protein-protein interactions of connexins: emerging roles. *Biochimica et Biophysica Acta* 1662: 22-41.
- Hipskind RA, Bilbe G. (1998). MAP kinase signaling cascades and gene expression in osteoblasts. *Frontiers in Bioscience* 3: 804-816.
- Ho AM, Johnson MD, Kingsley DM. (2000). Role of the mouse ank gene in control of tissue calcification and arthritis. *Science* 289: 265-70.
- Hornberg JJ, Bruggeman FJ, Binder B, Geest CR, Bij de Vaate M, Lankelma J, Heinrich R, Westerhoff V. (2005). Principles behind the multifarious control of signal Transduction: ERK phosphorylation and kinase/phosphatase control. *FEBS Journal* 272: 244-258.

- Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF. (1995). Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. *J Bone Min Res* 10: 1478-87.
- Hulley PA, Gordon F, Hough FS. (1998). Inhibition of Mitogen-Activated Protein Kinase Activity and Proliferation of an Early Osteoblast Cell Line (MBA 15.4) by Dexamethasone: Role of Protein Phosphatases. *Endocrinology* 139: 2423-2431.
- Hunter T. (2000). Signaling-2000 and beyond. *Cell* 100: 113-127.
- Idris AI, Rojas J, Greig IR., van't Hof RJ, Ralston SH. (2008). Aminobisphosphonates Cause Osteoblast Apoptosis and Inhibit Bone Nodule Formation In Vitro *Calcif Tissue Int* 82: 191–201.
- Jagdev SP, Coleman RE, Shipman CM, Rostami- H A, Croucher PI. (2001). The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. *British Journal of Cancer* 84: 1126–1134.
- Karin M, Hunter T. (1995). Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. *Curr Biol* 5: 747-757.
- Kato Y, Windle JJ, Koop BA, Mundy GR, Bonewald LF. (1997). Establishment of an osteocyte-like cell line, MLO-Y4. *J Bone Miner Res.* 12: 2014-2023.
- Katz S, Boland R, Santillán G. (2008). Purinergic (ATP) signaling stimulates JNK1 but not JNK2 MAPK in osteoblast-like cells: Contribution of intracellular Ca²⁺ release, stress activated and L-voltage-dependent calcium influx, PKC and Src kinases. *Archives of Biochemistry and Biophysics* 477: 244–252.

- Keyse SM. (2008). Dual-specificity MAP kinase phosphatases (MKPs) and cancer. *Cancer Metastasis Rev.* 27:253–261.
- Krieger NS, Tashjian AH. (1983). Inhibition of Stimulated Bone Resorption by Vanadate. *Endocrinology* 113: 324-328.
- Laemmli UK. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.
- Laird D, Puranam K, Revel J. (1991). Turnover and phosphorylation dynamics of connexin43 gap junction protein in cultured cardiac myocytes. *Biochem. J.* 273: 67-72.
- Lau KH, Baylink DJ. (1998). Molecular Mechanism of Action of Fluoride on Bone Cells. *Journal of Bone and Mineral Research* 13: 1660-67.
- Lau KH, Farley JR, Baylink DJ. (1985). Phosphotyrosyl- specific protein phosphatase activity of a bovine skeletal acid phosphatase: Comparison with the phosphotyrosyl protein phosphatase activity of skeletal alkaline phosphatase. *J Biol Chem* 260: 4653–4660.
- Lau KH, Farley JR, Freeman TK, Baylink DJ. (1989). A proposed mechanism of the mitogenic action of fluoride on bone cells: Inhibition of the activity of an osteoblastic acid phosphatase. *Metabolism* 38: 858–868.
- Lau KH, Tanimoto H, Baylink DJ. (1988). Vanadate stimulates bone cell proliferation and bone collagen synthesis in vitro. *Endocrinology* 123: 2858–2867.
- Lauf U, Giepmans BN, Lopez P, Braconnot S, Chen SC, Falk MM. (2002). Dynamic trafficking and delivery of connexons to the plasma membrane

and accretion to gap junctions in living cells, Proc. Natl. Acad. Sci. U. S. A. 99: 10446–10451.

Lenormand P, Sardet C, Pagès G, L'Allemain G, Brunet A, Pouyssegur J. (1993). Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J Cell Biol 122: 1079-88.

Liang F, Lee S, Liang J, Lawrence D, Zhang Z. (2005). The Role of Protein-tyrosine Phosphatase 1B in Integrin Signaling. The Journal of Biological Chemistry. 280: 24857–24863.

Majeska RJ, Rodan GA. (1982). The effect of 1,25(OH)₂D₃ on alkaline phosphatase in osteoblastic osteosarcoma cells. J Biol Chem 257: 3362-5.

Majeska RJ, Rodan SB, Rodan GA. (1980). Parathyroid hormone-responsive clonal cell lines from rat osteosarcoma. Endocrinology 107: 1494-503.

Maksumova L, Wang Y, Wong N, Le H, Pallen C, Johnson P. (2007). Differential function of PTP α and PTP α Y789 in T cells and regulation of PTP α phosphorylation at Tyr789 by CD45. The Journal of Biological Chemistry. 282: 20925-20932.

Menton DN, Simmons DJ, Chang SL, Orr BY. (1984). From bone lining cell to osteocyte--an SEM study. Anat Rec 209: 29-39.

Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Katri S, Selander KS. (2007). Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. European Journal of Pharmacology 570: 27–37.

- Mesnil M, Krutovskikh V, Piccoli C, Elfgang C, Traub O, Willecke K, Yamasaki H. (1995). Negative Growth Control of HeLa Cells by Connexin Genes: Connexin Species Specificity. *Cancer Research* 55: 629-639.
- Mikalsen SO, Kaalhus O. (1996). A characterization of pervanadate, an inducer of cellular tyrosine phosphorylation and inhibitor of gap junctional intercellular communication. *Biochim Biophys Acta* 1290: 308–18.
- Milhaud G, Labat ML, Moricard Y. (1983). (Dichloromethylene) diphosphonate-induced impairment of T-lymphocyte function. *Proc Natl Acad Sci USA* 80: 4469–4473.
- Morelli S, Scodelaro Bilbao P; Katz S; Lezcano V; Roldán E; Boland R; Santillán GE. (2010). Protein phosphatases: possible bosphosphonate binding sites mediating stimulation of osteoblast proliferation. *Archives of Biochemistry and Biophysics*. *En prensa*.
- Musil LS, Cunningham BA, Edelman GM, Goodenough DA. (1990). Differential phosphorylation of the gap junction protein connexin43 in junctional communication-competent and -deficient cell lines. *J Cell Biol* 111: 2077-2088.
- Nishimoto S, Nishida E. (2006). MAPK signalling: ERK5 versus ERK1/2. *EMBO reports* 7: 782–786.
- Pallen CJ. (2003). Protein tyrosine phosphatase a (PTPa): a Src family kinase activator and mediator of multiple biological effects. *Curr. Top Med. Chem.* 3: 821–835.
- Parfitt AM. (1994). Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. *J Cell Biochem* 55: 273-86.

- Paul J. (1975). En: Cell and Tissue culture. Churchill Livingstone Ed., Medical Division of Longman Group Lt., pág. 90.
- Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. *Endocr Rev* 22: 153-83.
- Pennanen N, Lapinjoki S, Urtti A, Monkkinen J. (1995). Effect of liposomal and free bisphosphonates on the IL-1b, IL-6 and TNFa secretion from RAW 264 cells *in vitro*. *Pharmacol Res* 12: 916-922.
- Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. (2005). Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. *The Journal of Biological Chemistry* 280: 7317-7325.
- Plotkin LI, Goellner J, Vyas K et al. (2007). A bisphosphonate analog that lacks anti-remodeling activity prevents osteocyte and osteoblast apoptosis *in vivo*. *J Bone Min Res*; 22(Suppl. 1): S4.
- Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. (2008). Connexin 43 Is Required for the Anti-Apoptotic Effect of Bisphosphonates on Osteocytes and Osteoblasts *In Vivo*. *J. Bone Miner. Res.* 23: 1712-1721.
- Plotkin LI, Manolagas SC, Bellido T. (2002). Transduction of Cell Survival Signals by Connexin-43 Hemichannels. *The Journal of Biological Chemistry* 277: 8648-8657.
- Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. (1999). Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. *J.Clin.Invest.* 104: 1363-1374.

- Price PA, Baukol SA. (1980). 1,25-Dihydroxyvitamin D₃ increases synthesis of the vitamin K-dependent bone protein by osteosarcoma cells. *J Biol Chem* 255: 11660-3.
- Raman M, Chen W, Cobb MH. (2007). Differential regulation and properties of MAPKs. *Oncogene* 26: 3100-3112.
- Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC. (2000). Bisphosphonates Directly Regulate Cell Proliferation, Differentiation, and Gene Expression in Human Osteoblasts. *Cancer Research* 60: 6001-6007.
- Reszka AA, Rodan GA. (2004). Nitrogen-containing bisphosphonate mechanism of action. *Mini Reviews in Medicinal Chemistry* 4: 711-719.
- Riggs BL, O'Fallon WM., Lane A, Hodgson SF, Wahner HW, Muhs J, Chao E, Melton LJ. (1994). Clinical Trial of Fluoride Therapy in Postmenopausal Osteoporotic Women: Extended Observations and Additional Analysis. *Journal of Bone and Mineral Research* 9: 265-275.
- Rogers MJ. (2003). New insights into the molecular mechanisms of action of bisphosphonates. *Current Pharmaceutical Design* 11: 196-214.
- Rogers MJ. (2004). From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. *Calcified Tissue International* 75: 451-461.
- Rogers RJ, Watts DJ, Russell RG. (1997). Overview of Bisphosphonates. *Cancer* 80: 1652-60.
- Rook MB, de Jonge B, Jongsma HJ, Masson-Pevet MA. (1990). Gap junction formation and functional interaction between neonatal rat cardiocytes in

culture: a correlative physiological and ultrastructural study. *J Membrane Biol.* 118: 179-192.

Roux PP, Blenis J. (2004). ERK y p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. *Microbiol Mol Biol Rev.* 68: 320-344.

Russell RG, Watts NB, Ebetino FH et al. (2008). Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. *Osteoporosis International* 19: 733–759.

Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH. (2007). Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy. *Ann. N.Y. Acad. Sci.* 1117: 209–257.

Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. (2004). Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. *Mol Cell.* 15: 713-725.

Saez JC, Berthoud VM, Branes MC, Martinez AD, Beyer EC. (2003). Plasma membrane channels formed by connexins: their regulation and functions. *Physiol. Rev.* 83: 1359–1400.

Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson D.D, Golub E, Rodan G. A. (1991). Bisphosphonate Action. Alendronate Localization in Rat Bone and Effects on Osteoclast Ultrastructure. *J. Clin. Invest.* 88: 2095-2105.

Scatchard, G. (1949). The attractions of proteins for small molecules and ions. *Ann. N.Y. Acad. Sci.* 51: 660-672.

- Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu C-T, Huang Z, Ramachandran C, Rodan SB and Rodan GA. (1996). Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate. *Proc Natl Acad Sci USA*. 93: 3068-3073.
- Shinoda H, Adamek G, Felix R et al. (1983). Structure-activity relationships of various bisphosphonates. *Calcified Tissue International*. 35: 87–99.
- Siller-Jackson AJ, Burra S, Gu S, Xia X, Bonewald LF, Sprague E, Jiang JX. (2008). Adaptation of connexin 43-hemichannel prostaglandin release to mechanical loading. *Journal of Biological Chemistry*. 283: 26374-26382.
- Simon AM, Goodenough DA, Paul DL. (1998). Mice lacking connexin40 have cardiac conduction abnormalities characteristic of atrioventricular block and bundle branch block. *Curr. Biol*. 8: 295–298.
- Snedecor G, Cochran W. (1967). *Statistical methods*. Ames, IA: Iowa State University Press. 120-134.
- Solan JL, Lampe PD. (2005). Connexin phosphorylation as a regulatory event linked to gap junction channel assembly. *Biochimica et Biophysica Acta* 1711: 154– 163.
- Swarup G, Cohen. S, Garbers DL. (1982). *Biochem. Biophys. Res. Commun.* I07, 1104-I 109.
- Thompson K, Rogers MJ, Coxon FP et al. (2006). Cytosolic entry of bisphosphonate drugs requires acidification of vesicles following fluid-phase endocytosis. *Molecular Pharmacology* 69: 1624–1632.
- Tonks, N. (2006). Protein tyrosine phosphatases: from genes, to function, to disease. *Nat. Rev. Mol. Cell Biol.* 7: 833–846.

- Towbin H, Staehelin T, Gordon J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci U S A.* 76: 4350-4.
- Tsuchimoto M, Azuma Y, Higuchi O, Sugimoto I, Hirata N, Kiyoki M, Yamamoto I. (1994). Alendronate Modulates Osteogenesis of Human Osteoblastic Cells In Vitro *Jpn. J. Pharmacol.* 66: 25-33.
- Twiss IM, Pas O, Ramp-Koopmanschap W, Den-Hartigh J, Vermeij P. (1999). The Effects of Nitrogen-Containing Bisphosphonates on Human Epithelial (Caco-2) Cells, an In Vitro Model for Intestinal Epithelium. *Journal of Bone and Mineral Research* 14: 784-791.
- Vander MM, Rubin CT, McLeod KJ, McCauley LK & Donahue HJ. (1996). Gap junctional intercellular communication contributes to hormonal responsiveness in osteoblastic networks. *J Biol Chem* 271: 12165-12171.
- Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE. (1997). Relationship between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease. *Ann Oncol.* 8: 1243-1250.
- Weinstein RS. (2000). True Strength. *J Bone Min Res.* 15: 621-25.
- Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD. (2009). Effects of Alendronate on the Proliferation and Osteogenic Differentiation of MG-63 Cells. *The Journal of International Medical Research* 37: 407-416.
- Zhang Y, Dong C. (2007). Regulatory mechanisms of mitogen-activated kinase signaling. *Cell Mol Life Sci.* 64: 2771-2789.

Zheng X, Resnick R, Shalloway D. (2000). A phosphotyrosine displacement mechanism for activation of Src by PTP α . The EMBO Journal. 19: 964-978.

Zheng X, Shalloway D. (2001). Two mechanisms activate PTPalpha during mitosis. EMBO J. 20:6037-6049.